Neulasta 10 mg (Pegfilgrastim SOLUTION) 10 MG

Neulasta 10 mg is a pegfilgrastim solution for subcutaneous use, designed to support certain medical treatments. This product is manufactured by Amgen Canada Inc. and is commonly associated with supportive care in cancer therapy.

Strength

10 MG

Pack Size

0.6ML

Manufacturer / TM Owner

AMGEN CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Neulasta 10 mg is used to stimulate the production of white blood cells, which can be affected by certain medical treatments. It is often utilized in supportive care for patients undergoing chemotherapy to help reduce the risk of infections. The primary active ingredient, pegfilgrastim, works by encouraging the bone marrow to produce more white blood cells, which are crucial for the body's immune response.

Side Effects

Common effects of Neulasta 10 mg may include mild to moderate bone and muscle aches, as well as fatigue. Some individuals might experience headaches or mild nausea. These effects are generally temporary and should be discussed with a healthcare provider if they persist or worsen.

Precautions & Warnings

Neulasta 10 mg should be handled with care and stored as directed. It is important to follow the instructions provided by a healthcare professional regarding its use. Patients should inform their healthcare provider about any allergies or medical conditions before using this medication.

Avoid Interactions

Neulasta 10 mg may interact with other medications, particularly those that affect the immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the body's response to this medication.

Frequently Asked Questions

Neulasta 10 mg is used to stimulate the production of white blood cells, often in supportive care for patients undergoing chemotherapy.

Neulasta 10 mg is administered via subcutaneous injection, typically by a healthcare professional.

Common side effects may include bone and muscle aches, fatigue, headaches, and mild nausea.

It is important to discuss all current medications with a healthcare provider to avoid potential interactions.

Neulasta 10 mg should be stored as directed by the manufacturer, typically in a refrigerator.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.